Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Introduction to lisinopril-hydrochlorothiazide combination.

E Miller1

  • 1ICI Americas Inc., Wilmington, Delaware.

Journal of Human Hypertension
|December 1, 1991
PubMed
Summary

Combining lisinopril and hydrochlorothiazide (L/HCTZ) offers superior blood pressure reduction compared to monotherapy. This combination therapy enhances antihypertensive effects, providing better blood pressure control for patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acellular pertussis vaccine given by accelerated schedule: response of preterm infants.

Archives of disease in childhood. Fetal and neonatal edition·2004
Same author

Anencephaly-something missing from the archaeological record?

Paleopathology newsletter·2003
Same author

Sero-epidemiology of mumps in western Europe.

Epidemiology and infection·2003
Same author

Severe and unrecognised: pertussis in UK infants.

Archives of disease in childhood·2003
Same author

Measurement and interpretation of pneumococcal IgG levels for clinical management.

Clinical and experimental immunology·2003
Same author

Nutrient removal from wastewaters using high performance materials.

Water science and technology : a journal of the International Association on Water Pollution Research·2003

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Clinical Pharmacy

Background:

  • Two fixed-dose combinations of lisinopril and hydrochlorothiazide (L/HCTZ) are available.
  • Current marketing authorizations rely on dose-ratio and parallel titration studies.

Purpose of the Study:

  • To evaluate the antihypertensive efficacy of L/HCTZ combinations compared to monotherapy.
  • To assess the effectiveness of L/HCTZ in patients with essential hypertension.

Main Methods:

  • A randomized dose-ratio study involving 209 patients with sitting diastolic blood pressure (DBP) of 90-115 mm Hg.
  • A 12-week double-blind parallel titration study with 394 patients (sitting DBP 90-120 mm Hg) comparing lisinopril, HCTZ, and L/HCTZ.

Main Results:

  • L/HCTZ 20 mg/12.5 mg and 20 mg/25 mg showed significantly greater antihypertensive effects than monotherapy (P ≤ 0.01).
  • L/HCTZ 20 mg/6.25 mg was more effective than hydrochlorothiazide monotherapy but not lisinopril monotherapy.
  • The L/HCTZ group demonstrated significantly greater blood pressure reduction than either monotherapy (P ≤ 0.01).

Conclusions:

  • Concomitant therapy with lisinopril and hydrochlorothiazide provides additive blood pressure reduction beyond individual components.
  • Combination therapy offers enhanced efficacy for managing hypertension.
  • Further studies are exploring new L/HCTZ combinations to expand treatment options.

Related Experiment Videos